ARCT

Arcturus Therapeutics Holdings Inc. (ARCT) - Q3 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2025. Arcturus Therapeutics is a commercial messenger RNA (mRNA) medicines company focused on liver and respiratory rare disease therapeutics and infectious disease vaccines. The company recently transitioned to a commercial stage following the approval of its self-amplifying mRNA (sa-mRNA) vaccine, KOSTAIVE (ARCT-154), in Japan (2023) and the European Union (February 2025). Commercial sales in Japan began in October 2024.

Key Financial Metrics

Liquidity & Debt: The company holds $180.4 million in cash and cash equivalents and $56.9 million in restricted cash. It maintains a $50.0 million revolving credit facility with Wells Fargo, secured by $55.0 million in pledged cash. No amounts were drawn on this facility during Q3 2025.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 59% in Q3 2025 compared to Q3 2024, and 42% for the nine-month period. This was primarily driven by lower collaboration revenue from CSL Seqirus due to reduced supply agreement revenue and less amortization of deferred revenue as the KOSTAIVE program transitions from development to commercialization.
• Expense Reduction: Operating expenses decreased 36% in Q3 and 38% for the nine months ended September 30, 2025. Research and Development (R&D) expenses dropped 41% (Q3) and 42% (9M), largely due to lower manufacturing and clinical costs for the LUNAR-COVID program and reduced share-based compensation.
• Net Loss: While the net loss increased on a quarterly basis ($13.4M vs $6.9M), the nine-month net loss improved significantly ($36.7M vs $50.9M) due to the substantial reduction in operating expenses.

Guidance, Outlook, and Risks

• Regulatory Updates: The FDA requested a delay in the Biologics License Application (BLA) submission for KOSTAIVE in the U.S. in September 2025, citing a need for additional clinical endpoint efficacy data. A Marketing Authorization Application (MAA) was submitted to the UK in June 2025, with approval expected in Q1 2026.
• Clinical Progress:
  • LUNAR-CF (ARCT-032): Interim Phase 2 results showed reductions in mucus burden in Class I Cystic Fibrosis participants. The study is ongoing.
  • LUNAR-OTC (ARCT-810): Positive Phase 2 data showed significant decreases in glutamine levels and increased ureagenesis function in OTC deficiency patients.
  • Influenza: Phase 1 data for the seasonal influenza candidate (ARCT-2138) and pandemic H5N1 candidate (ARCT-2304) demonstrated robust immune responses.
• Risks & Contingencies:
  • Internal Controls: The company disclosed a continuing material weakness in internal control over financial reporting related to IT general controls (user access, change management, and operations).
  • Legal Proceedings: Arcturus filed a lawsuit in September 2025 against AbbVie and Capstan Therapeutics alleging trade secret misappropriation and breach of contract.
  • Partner Risk: Potential separation or spin-off of CSL Seqirus from CSL Limited could disrupt the strategic collaboration.
  • Government Shutdown: A U.S. federal government shutdown beginning October 1, 2025, poses risks to regulatory review timelines and funding access.

Investor Verification Checklist

• Verify the specific data requirements and timeline for the delayed U.S. BLA submission for KOSTAIVE.
• Monitor the progress and outcome of the trade secret misappropriation lawsuit filed against AbbVie and Capstan Therapeutics.
• Assess the impact of the ongoing material weakness in IT general controls on future financial reporting reliability.
• Track the commercial uptake of KOSTAIVE in Japan and the EU, and the status of the UK MAA approval.
• Review the cash burn rate relative to the $237.2 million cash balance to determine runway for ongoing Phase 2 trials.